Krystal Biotech awarded director Mason Christopher 1,658 derivative securities in transactions dated 2026-09-14. The award was recorded at $0 per share and classified as transaction code A, identifying it as an award or grant rather than an open-market purchase or sale for investors tracking insider activity.
Key Highlights
- The transactions were dated 14 September 2026.
- Transaction code A identifies the activity as an award or grant.
- The derivative securities carried a stated value of $0 per share.
Krystal Biotech, Inc. (NASDAQ: KRYS) awarded director Mason Christopher 1,658 derivative securities. The transaction represents an award to a named director, with the securities recorded under the company’s insider activity.
14 September 2026 Award Covers Derivative Securities
Krystal Biotech’s transaction record dates the activity to 14 September 2026. The stated consideration is $0 per share. The securities are associated with Christopher’s award from Krystal Biotech. The reported activity is presented as an award event, so it describes derivative securities granted to the director rather than securities acquired through an open-market purchase. The $0 per-share amount applies to the derivative securities covered by the award. Christopher is the participant associated with the transaction.
FAQs
Q: What did Mason Christopher receive from Krystal Biotech?
A: Mason Christopher received 1,658 derivative securities from Krystal Biotech. He is identified as a director, and the transaction was classified as an award or grant.
Q: Was the Krystal Biotech insider transaction a purchase or sale?
A: The transaction was recorded as an award of derivative securities rather than an open-market purchase. The stated consideration for the derivative securities was $0 per share.
Q: When was Krystal Biotech’s derivative-security award recorded?
A: The transactions involving Mason Christopher were dated 14 September 2026. The award covered derivative securities at a stated value of $0 per share.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.